Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9373023 | 0.81 | APP (0.38) | MAPTHTTNPSR1MEN1KMT2A | |
| SCHEMBL9724142 | 0.81 | ALDH1A1 (0.39) | MAPTFBP1HAO1L3MBTL1USP7 | |
| SCHEMBL9724080 | 0.80 | KDM4E (0.51) | MEN1KMT2AFBP1L3MBTL1USP7 | |
| SCHEMBL9724103 | 0.78 | ALDH1A1 (0.39) | MAPTSMN1; SMN2MEN1KMT2AICAM1 | |
| SCHEMBL7593054 | 0.78 | ALDH1A1 (0.43) | MAPTCYP2C9CYP2C19HAO1ICAM1 | |
| SCHEMBL9724212 | 0.72 | ALDH1A1 (0.50) | MAPTNPSR1MEN1KMT2ACYP2C9 | |
| SCHEMBL6382520 | 0.72 | MAOA (0.38) | MAPTHTTMAOAMAOBMEN1 | |
| SCHEMBL6922597 | 0.71 | MAOA (0.40) | MAPTHTTSMN1; SMN2NPSR1NOD2 | |
| SCHEMBL6928967 | 0.71 | MEN1 (0.43) | MAPTHTTSMN1; SMN2NPSR1NOD2 | |
| SCHEMBL6486705 | 0.70 | PKM (0.53) | HSD17B10CYP2C9CYP2C19HAO1USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1442041-A1 | AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040110809-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | disclosed |
| EP-1419161-A1 | SUBSTITUTED-HETEROARYL-7-AZA 2.2.1]BICYCLOHEPTANES FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-05-19 | — | — | EP | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370538-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
| US-6599916-B2 | Treating a disease or condition in a mammal, wherein the alpha 7 nicotinic acetylcholine receptor is implicated, Alzheimer's disease, pre-senile dementia (mild cognitive impairment), or senile dementia. | PHARMACIA & UPJOHN COMPANY | 2003-07-29 | — | — | US | disclosed |
| EP-1311505-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE ( NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS ) | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002015662-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002017358-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| CN-1321153-A | telomerase inhibitors and methods of use thereof | GERON CORP (US) | 2001-11-07 | — | — | CN | disclosed |
| WO-2001002377-A9 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORP (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-1109796-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | Geron Corporation (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001002377-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
| WO-1993003719-A1 | ARYLALKYLETHER AND ARYLALKYLTHIOETHER INHIBITORS OF LIPOXYGENASE ENZYME ACTIVITY | ABBOTT LABORATORIES (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5183818-A | Also for inhibiting leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1993-02-02 | — | — | US | disclosed |
| US-5158971-A | Antiallergens, antiinflammatory agents | LILLY INDUSTRIES LIMITED (GB) | 1992-10-27 | — | — | US | disclosed |
| EP-0459748-A2 | Thien-2-yl methylurea derivatives as leukotriene inhibitors | LILLY INDUSTRIES LIMITED (GB) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110809-A1 | Metalloproteinase inhibitors | MMP9, MMP2, MMP3 | MAPT 4179/4885HTT 4695/4885SMN1; SMN2 3091/4885 |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | MALT1, WFS1, NR5A1 | MAPT 4385/4885HTT 2464/4885SMN1; SMN2 1751/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | MAPT 4451/4885HTT 4139/4885SMN1; SMN2 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.